Q1.The global Contract Development and Manufacturing Industry (CDMO) has witnessed steep growth over the past few years. What is your perspective on the evolution of the CDMO Industry and how is it shaping today‘s market?

1. 88% of EU FMD CMOs are concerned that equipment shortages will affect their ability, or customer’s ability to comply with the regulations. Do you think this concern is warranted and why?

What do you think is the biggest hurdle when it comes to serialization in the industry?
The huge volume of data that will be generated and shared across the industry presents the greatest challenge. Serialization creates the need for a connected supply chain and those companies that leverage existing multi-tenant networks can take advantage of multiple, seamless connections with their partners.

How are Indian generics companies fairing in the competitive race to serialize and ship medicines to the US?
Though the serialization deadline has passed for the Drug Supply Chain Security Act (DSCSA)in the US, companies across the globe are still in racing to serialize and ship products to the US market, as a result ofthe FDA’s decision to delay active enforcement until November 2018.

1. What does this approval mean to Idifarma?
It’s a great opportunity for growth, boosting our GMP capabilities with capsule filling in addition to immediate and modified release tablets. It is also a significant milestone in our journey so far, helping us to become a leading CDMO for small-scale niche products in solid oral forms.

1. Will this merger change any of your organizational structure and framework?
The partnership is not a merger, it is a collaboration between Recipharm and the Clinical Trial Consultants (CTC) to allow both companies to offer a complete service from formulation development to first in human studies.

Show more
Show less
Subscribe to our Newsletter
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok